What is it about?
Pseudomonas(p.) aeruginosa is one of the leading reasons for nosocomial infections. The pathogenicity of P. aeruginosa is related to its inherent antimicrobial resistance and the diverse virulence factors of this bacterium. Owing to the specific role of exotoxin A in P. aeruginosa pathogenesis, it is known as a promising therapeutic candidate to develop antibodies as an alternative for antibiotics.
Featured Image
Photo by ANIRUDH on Unsplash
Why is it important?
In summary, a recombinant human scFv which is neutralizing exotoxin P. aeruginosa recommended as a promising treatment of infections caused by P. aeruginosa.
Perspectives
In my perspective,data from computational biology could provide protein-protein interaction information between scFv antibody/domain I exotoxin A and offers new insights into antibody development and therapeutic expansion.
Zahra Shadman
Read the Original
This page is a summary of: In silico Validation of Pseudomonas aeruginosa Exotoxin A Domain I
Interaction with the Novel Human scFv Antibody, Infectious Disorders - Drug Targets, August 2023, Bentham Science Publishers,
DOI: 10.2174/1871526523666230329104537.
You can read the full text:
Contributors
The following have contributed to this page
